logo
  • Home
  • Technologies
    • Live Cell Encapsulation
    • Research & Development
    • Cancer
    • Diabetes
    • Cannabinoids
  • Company
    • Management
    • Board of Directors
    • Governance
    • Medical and Scientific Advisory Board
    • International Diabetes Consortium
  • Investors
    • Overview
    • News / Events
    • Shareholder Calls / Presentations
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • News & Media
    • Press Releases
    • Articles
    • Reports
    • Media
    • Photo Gallery
  • Contact

Press Releases

Navigation Toggle Navigation
  • Overview
  • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Shareholder Calls / Presentations
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
  • Quick Links
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
  • All News
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • Oct 10, 2016

PharmaCyte Biotech Cannabinoid Research Shows Promise for Success

  • Sep 15, 2016

PharmaCyte’s CEO Discusses Development of its Pancreatic Cancer Therapy

  • Sep 1, 2016

PharmaCyte Biotech Reports on Progress in Its Medical Cannabis Program

  • Aug 2, 2016

Dr. Mark L. Rabe Presents PharmaCyte Biotech’s Ongoing Research at Cannabis Cancer Forum

  • Jul 29, 2016

PharmaCyte Biotech Releases Shareholder Call Playback Information

  • Jul 25, 2016

PharmaCyte Biotech Shareholder Call Update

  • Jul 19, 2016

As Diabetes Becomes Global Epidemic, PharmaCyte Biotech's Insulin Producing Cells Receive 20 Years of Protection

  • Jul 14, 2016

PharmaCyte Biotech Receives Patent Protection of the Melligen Cells to Treat Diabetes

  • Jul 11, 2016

PharmaCyte Biotech to Hold Shareholder Call

  • Jul 7, 2016

PharmaCyte Biotech Uses "Artificial Liver" to Treat Advanced Pancreatic Cancer

RSS
  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next »

Contact Us

PharmaCyte Biotech, Inc.
3960 Howard Hughes Parkway, Suite 500
Las Vegas, Nevada 89169
Office Number: 917.595.2850
Facsimile Number: 917.595.2851
Email: info@PharmaCyte.com

Latest News

  • PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells July 5, 2022
  • PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value June 15, 2022